Hypothyroidism Market Set to Grow Through 2034 as Emerging Therapies Like XP-8121 Advance Beyond Standard Levothyroxine Care | DelveInsight

DelveInsight's "Hypothyroidism Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of hypothyroidism, historical and forecasted epidemiology, as well as the hypothyroidism market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Hypothyroidism Market Report @ https://www.delveinsight.com/report-store/hypothyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Hypothyroidism Market Report
• In January 2026, AbbVie announced result of A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism.
• In July 2025, Oliva Therapeutics announced the relaunch and immediate availability of THYQUIDITY (levothyroxine sodium oral solution). In partnership with Jerome Stevens Pharmaceuticals, a US-based prescription pharmaceutical manufacturer and packager, the launch represents the first branded product launch for Oliva Therapeutics and expands upon a joint endocrine-focused portfolio and pipeline.
• In April 2025, Jerome Stevens Pharmaceuticals completed the acquisition of THYQUIDITY from Azurity Pharmaceuticals.
• Iodine deficiency is the leading global cause of hypothyroidism, while in the United States, autoimmune thyroid disease (Hashimoto thyroiditis) is the most common cause.
• Based on NHANES data, nearly 10% of the US population was affected by hypothyroidism between 2009 and 2012.
• Analysis of Optum data indicates a rising prevalence of hypothyroidism in the US, with rates increasing from 9.5% in 2012 to 11.7% in 2019.
• The rate of hypothyroidism was highest among females and among those older than 60 years of age.
• Among patients enrolled in the NHANES 2009-2010 and 2011-2012 cycles, approximately 29.6% were aged 12-29 years, 32.2% were aged 30-49 years, 34.3% were aged 50-79 years, and only 3.9% were aged 80 years or older.
• Hypothyroidism prevalence in the US based on NHANES data from 1988-1994 (published 2002) was estimated at 0.3% for overt hypothyroidism and 4.3% for subclinical hypothyroidism.
• A 2019 meta-analysis of 20 studies reported a 4.7% prevalence of undiagnosed hypothyroidism in Europe, including 0.65% clinical and 4.11% subclinical cases.
• The Hypothyroidism Companies include Jerome Stevens Pharmaceuticals, Olive Therapeutics, Azurity Pharmaceuticals, and Xeris BioPharma, among others.
• Promising Hypothyroidism Therapies include THYQUIDITY and XP-8121, among others.

Get a Free sample for the Hypothyroidism Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/hypothyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Hypothyroidism?
Hypothyroidism is a common endocrine disorder in which the thyroid gland does not produce enough thyroid hormones to meet the body's metabolic needs. This condition can cause fatigue, weight gain, cold intolerance, dry skin, constipation, depression, and slowed heart rate. Common causes include autoimmune thyroiditis, thyroid surgery, radioactive iodine therapy, and iodine deficiency. Diagnosis involves measuring thyroid-stimulating hormone (TSH) and thyroid hormone levels. Treatment typically consists of lifelong thyroid hormone replacement therapy, which effectively restores normal hormone levels and relieves symptoms.

Hypothyroidism Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of Hypothyroidism
• Diagnosed Prevalent Cases of Hypothyroidism
• Age-specific Cases of Hypothyroidism
• Gender-specific Cases of Hypothyroidism
• Severity-specific Cases of Hypothyroidism

Download the report to understand which factors are driving Hypothyroidism epidemiology trends @ https://www.delveinsight.com/report-store/hypothyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Hypothyroidism Approved Therapies
• THYQUIDITY (levothyroxine sodium): Jerome Stevens Pharmaceuticals/Oliva Therapeutics
THYQUIDITY is indicated for hypothyroidism, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. In November 2020, THYQUIDITY received US FDA approval for the treatment of hypothyroidism. In collaboration with Oliva Therapeutics, THYQUIDITY remains available without interruption, providing current patients consistency as well as offering new patients an alternative high-quality levothyroxine sodium therapy. Levothyroxine is also available in different generic versions marketed under various brand names like EUTHYROX, ELTROXIN, LEVOXYL, THYRONORM, and SYNTHROID, with the active ingredient listed as levothyroxine sodium. Off-label options like ARMOUR THYROID, a prescription of thyroid hormones (T3 and T4) obtained from pig thyroid, are also used in some patients but require caution due to variable hormone content.

Hypothyroidism Pipeline Analysis
• XP-8121: Xeris Biopharma
XP-8121 employs the company's XeriSol formulation technology to enable a novel once-weekly subcutaneous injection of levothyroxine. This novel formulation significantly increases the bioavailability of levothyroxine, reducing overall drug exposure and enabling a dosing regimen with the potential to mitigate the many challenges associated with achieving and maintaining a normal level of TSH with daily oral formulations of levothyroxine. In May 2024, Xeris Biopharma announced topline results from its completed Phase II study of XP-8121 for the treatment of adults with hypothyroidism. In its Q2 2025 presentation, the company projected initiation of the Phase III trial in 2026, with topline results anticipated in 2029 and potential regulatory approval in 2030.

Hypothyroidism Companies
Jerome Stevens Pharmaceuticals, Olive Therapeutics, Azurity Pharmaceuticals, Xeris BioPharma, among others

Discover more about therapies set to grab major Hypothyroidism market share @ https://www.delveinsight.com/sample-request/hypothyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Hypothyroidism Market Outlook
The therapeutic landscape for hypothyroidism is well-established, with a large and mature global market driven by the high prevalence of the condition. Levothyroxine remains the standard of care, available in multiple branded and generic formulations, with products like THYQUIDITY offering oral solution delivery for patients with swallowing difficulties. Off-label and adjunctive options, such as ARMOUR THYROID (desiccated thyroid extract) and CYTOMEL (liothyronine), are used in select cases where levothyroxine monotherapy does not provide adequate symptom control. Despite these options, there is currently limited development in the emerging pipeline, with drug candidates like XP-8121 being investigated in the Phase III stage of clinical trial. Innovation in the space is largely focused on optimizing formulations, delivery methods, and patient adherence rather than introducing new molecular targets. In the marketed class of drugs, the cornerstone of therapy includes thyroid hormone receptor agonists such as THYQUIDITY, which replicate the action of triiodothyronine (T3) by binding to nuclear THRα or THRβ receptors, activating thyroid hormone response elements on DNA that trigger transcription of genes regulating metabolism, lipid and carbohydrate processing, and thermogenesis.

Scope of the Hypothyroidism Market Report
• Study Period: 2020-2034
• Forecast Period: 2025-2034
• Coverage: 7MM (US, EU4 [Germany, France, Italy, and Spain] and the UK, and Japan)
• Hypothyroidism Companies: Jerome Stevens Pharmaceuticals, Olive Therapeutics, Azurity Pharmaceuticals, Xeris BioPharma, among others
• Hypothyroidism Therapies: THYQUIDITY, XP-8121, among others
• Hypothyroidism Market Segmented by: Region, Therapies
• Hypothyroidism Therapeutic Assessment: Hypothyroidism current marketed and emerging therapies
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Hypothyroidism Unmet Needs, KOL's views, Analyst's views, Hypothyroidism Market Access and Reimbursement

To know more about Hypothyroidism companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/hypothyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Hypothyroidism
4. Key Events
5. Hypothyroidism Epidemiology and Market Forecast Methodology
6. Hypothyroidism Market Overview at a Glance
7. Disease Background and Overview: Hypothyroidism
8. Treatment and Management
9. Epidemiology and Patient Population of Hypothyroidism in the 7MM
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. Hypothyroidism: Seven Major Market Analysis
14. Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.